0001209191-22-014145.txt : 20220301
0001209191-22-014145.hdr.sgml : 20220301
20220301171124
ACCESSION NUMBER: 0001209191-22-014145
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220225
FILED AS OF DATE: 20220301
DATE AS OF CHANGE: 20220301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Meyers James R
CENTRAL INDEX KEY: 0001387521
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 22699581
MAIL ADDRESS:
STREET 1: GILEAD SCIENCES, INC.
STREET 2: 333 LAKESIDE DRIVE
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-02-25
0
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0001387521
Meyers James R
C/O SANGAMO THERAPEUTICS, INC.
7000 MARINA BLVD.
BRISBANE
CA
94005
1
0
0
0
Common Stock
2022-02-25
4
A
0
12500
0.00
A
35700
D
Stock Option (Right to Buy)
5.90
2022-02-25
4
A
0
25000
0.00
A
2032-02-24
Common Stock
25000
25000
D
Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.
Includes 1,667 shares subject to the Reporting Person's November 22, 2019 RSU grant that will vest in one final annual installment on November 22, 2022, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through such date and subject to acceleration as provided in the 2018 EIP.
The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
James R. Meyers, by /s/ Ron A. Metzger, Attorney-in-Fact
2022-03-01